Pentoxifylline

DRUG INFORMATION

  ADULT
    - DOSAGE & ADMINISTRATION The usual dosage of pentoxifylline in extended-release
      tablet form is one tablet (400 mg) three times a day with meals.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'dosage and
      administration', retrieved 2026-08-29
    - If patients develop these effects it is recommended that the dosage be lowered to
      one tablet twice a day (800 mg/day).
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'dosage and
      administration', retrieved 2026-08-29
    - DOSAGE & ADMINISTRATION The usual dosage of pentoxifylline in extended-release
      tablet form is one tablet (400 mg) three times a day with meals. While the effect
      of pentoxifylline extended-release tablets may be seen within 2 to 4 weeks, it is
      recommended that treatment be continued for at least 8 weeks. Efficacy has been
      demonstrated in double-blind clinical studies of 6 months duration. Digestive and
      central nervous system side effects are dose related.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Safety and effectiveness in pediatric patients have not been established.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'pediatric use',
      retrieved 2026-08-29

  RENAL IMPAIRMENT
    - In patients with severe renal impairment (creatinine clearance below 30 mL/min)
      reduce dose to 400 mg once a day.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'dosage and
      administration', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Dosing information cannot be provided for patients with hepatic impairment.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'dosage and
      administration', retrieved 2026-08-29

  PREGNANCY
    - Category C: Teratogenicity studies have been performed in rats and rabbits using
      oral doses up to 576 mg/kg and 264 mg/kg, respectively.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'pregnancy',
      retrieved 2026-08-29
    - On a weight basis, these doses are 24 and 11 times the maximum recommended human
      daily dose (MRHD); on a body-surface-area basis, they are 4.2 and 3.5 times the
      MRHD.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'pregnancy',
      retrieved 2026-08-29
    - No evidence of fetal malformation was observed.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Pentoxifylline and its metabolites are excreted in human milk.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'nursing
      mothers', retrieved 2026-08-29
    - Because of the potential for tumorigenicity shown for pentoxifylline in rats, a
      decision should be made whether to discontinue nursing or discontinue the drug,
      taking into account the importance of the drug to the mother.
      Source: US FDA label for pentoxifylline (Pentoxifylline), section 'nursing
      mothers', retrieved 2026-08-29